All subjects had ejection fraction 50%, and they were randomized to receive either tirzepatide or placebo, 364 in the tirzepatide group and 367 in the placebo group
According to the MHRA-approved Summary of Product Characteristics (SmPC), nausea is very common (affecting more than 1 in 10 people), while abdominal pain, vomiting, diarrhoea, and constipation are common (affecting between 1 in 100 and 1 in 10 people)
Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease
Vitamin B shots are a safe way to improve your health in a variety of ways
Because the symptoms are subtle, patients may not realize anything is wrong until vision blurs from cataract or intraocular pressure (IOP) rise
Who Can Get It and Who Shouldn't